Detection of AmpC β Lactamases in Gram-negative Bacteria

AmpC β-lactamases are clinically important cephalosporinases encoded on the chromosomes of many Enterobacteriaceae and a few other organisms, where they mediate resistance to cephalothin, cefazolin, cefoxitin, most penicillins, and β-lactamase inhibitor/β-lactam combinations. The increase in antibiotic resistance among Gram-negative bacteria is a notable example of how bacteria can procure, maintain and express new genetic information that can confer resistance to one or several antibiotics. Detection of organisms producing these enzymes can be difficult, because their presence does not always produce a resistant phenotype on conventional disc diffusion or automated susceptibility testing methods. These enzymes are often associated with potentially fatal laboratory reports of false susceptibility to β-lactams phenotypically. With the world-wide increase in the occurrence, types and rate of dissemination of these enzymes, their early detection is critical. AmpC β-lactamases show tremendous variation in geographic distribution. Thus, their accurate detection and characterization are important from epidemiological, clinical, laboratory, and infection control point of view. This document describes the methods for detection for AmpC β-lactamases, which can be adopted by routine diagnostic laboratories.

[1]  A. Pandey,et al.  Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli. , 2013, Indian journal of pathology & microbiology.

[2]  Jaspal Kaurthe Increasing antimicrobial resistance and narrowing therapeutics in typhoidal salmonellae. , 2013, Journal of clinical and diagnostic research : JCDR.

[3]  R. Laxminarayan,et al.  Communicating trends in resistance using a drug resistance index , 2011, BMJ Open.

[4]  Kenneth S. Thomson,et al.  Extended-Spectrum-β-Lactamase, AmpC, and Carbapenemase Issues , 2010, Journal of Clinical Microbiology.

[5]  R. Bonomo,et al.  Three Decades of β-Lactamase Inhibitors , 2010, Clinical Microbiology Reviews.

[6]  P. Coll,et al.  A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli. , 2006, Enfermedades infecciosas y microbiologia clinica.

[7]  N. Hanson AmpC beta-lactamases: what do we need to know for the future? , 2003, The Journal of antimicrobial chemotherapy.

[8]  N. Hanson,et al.  Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCR , 2002, Journal of Clinical Microbiology.

[9]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[10]  G. Papanicolaou,et al.  Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae , 1990, Antimicrobial Agents and Chemotherapy.